ajax loader

Loading...


Ride-the-Wave Strategy – Best for Stock Traders

Ride-the-Wave targets multi-day price momentum following a company’s earnings announcement (EA). With this strategy:

  1. Buy a stock one day post-EA if a stock reacts positively post-earnings:
    1. Near the close of trading the EA-day for a pre-market-EA
    2. Near the close of the following day for a post-market-EA
  2. Sell-to-close after 7-10 days, or possibly earlier if a desired price target is reached

Similarly,

  1. short a stock one day post-EA if a stock reacts negatively post-earnings:
    1. near the close of trading the EA-day for a premarket-EA
    2. near the close of the following day for a post-market-EA
  2. then buy-to-close after 7-10 days, or possibly earlier if a desired price target is reached

Important: Ride-the-Wave is predicated on significant price momentum triggered by an EA. The 7-10 day scenario is the maximum trade hold-time. If you see post EA-momentum is halted or reversed by a significant opposite move, re-evaluate your presence in the trade.

This popular StockEarnings screen below will give you a list of stocks that historically exhibit significant price momentum following an EA for the next seven days:

  1. Stocks exhibiting positive post-EA price moves are buy-candidates
  2. Stocks exhibiting negative post-EA price moves are sell/short-candidates

The screen includes those stocks whose Earnings just came out in last two days.

Screen criteria:

  1. Earnings Date Start Date : Current Date + -1 Day
  2. Earnings Date End Date : Current Date + -2 Days
  3. Predicted Move (Next Day) Max : 7%
  4. Predicted Move (On 7th Day) Min : 7%

Strategy Guideline:

  1. Buy the stock if stock has reacted positively. Short the stock if stock has reacted negatively (see above).
  2. Close the position in 7-10 days, or possibly earlier based on price move.

Volatility Crush Strategy - Best for Options Traders

The Volatility Crush strategy is used with stocks that typically experience relatively low-to-moderate price moves (≤4%) following their Earnings Announcements (EA). The basic trade idea is to sell put or call options right before the EA, collecting a credit when options premium is very high due to elevated implied volatility (IV). You then close the position right after the EA by buying the option back much cheaper due to the significant drop in IV that occurs after the mystery of the EA disappears. In assessing this trade, you need to do your homework to ensure you collect sufficient premium to make the trade worthwhile.

This trade is practical due to the low-to-moderate price-move after the EA, which generally won’t significantly affect the options price, unlike an “action” stock, which experience great price moves post-EA. With these symbols, if you’re on the right side of the price move, that’s a great thing. But if you’re on the wrong side of the move, not so great. Consequently, by minimizing the effect of the post-EA price move, you have a much better chance to profit from the reduction in IV without it being ruined by a violent price move.

For this trade, open the position either (1) the night before the EA when the company announces earnings or (2) during the EA day when it announces post-market, generally capturing IV at or close to its peak.

For this trade, open the position either (1) the night before the EA when the company announces earnings or (2) during the EA day when it announces post-market, generally capturing IV at or close to its peak.

This popular stockearnings screen will give you a list of stocks which do not react more than 4% fpost-EA. It includes only those stocks whose earnings are releasing next day.

Screen criteria:

  1. Earnings Date Start Date : Current Date + 1
  2. Earnings Date End Date : Current Date + 1
  3. Predicted Move (Next Day) Max : 4%
  4. Options Type: Weekly

Strategy Guideline:

  1. Options Strategy: Sell Call and Put
  2. Options Strike Price: Current Stock Price – (% Predicated Move x 2)
  3. Expiration Date: It should generally be the closest expiry immediately after the EA.
  4. Buy Insurance: Buying back Call and Put at Strike price which 10% lower than Sell Strike Price is optional but recommended.

Watch Video for More Detail

Volatility Rush Strategy - Best for Options Traders

The Volatility Rush takes advantage of increasing options premiums into earnings announcements (EA) caused by an anticipated rise in Implied Volatility (IV). With this strategy, Buy a Call and Put at-the-money (a long straddle) 2-3 weeks before the EA when IV is lower. Sell the position either (1) the night before the EA when the company announces earnings pre-market, or (2) during the EA day when it announces post-market, generally capturing IV at or close to its peak.

This popular screen will give you a list of stocks whose Options premiums tend to rise into Earnings. It includes only those stocks whose Earnings are at least two weeks away from today.

Screen criteria:

  1. Earnings Date Start Date : Current Date + 15 Days
  2. Earnings Date End Date : Current Date + 30 Days
  3. Predicted Move (Next Day) Min : 5%
  4. Options Type: Weekly or Monthly if that lines up with the two to three-week lead-time for entering the trade

Strategy Guideline:

  1. Buy a Straddle at or close to the money two to three weeks pre-EA.
  2. Sell the position either the night before the EA when the company announces earnings pre-market, or during the EA day when it announces post-market.
  3. Expiration date should generally be the closest expiry immediately after the EA.
  4. Straddle price should not be more 60% of predicted move.

Predicted Move (Volatility)

Similar to Implied Volatility in Options. Expected volatility % based on our Proprietary Volatility Predication Model. We are expecting that stock price will likely to reach % in either direction by the end of next trading session after Earnings are released and not necessarily the closing volatility %.

Why is it important?

    This indicator helps

  1. Knowing expected volatility in stocks after Earnings helps to decide trading stocks before Earnings Announcement.
  2. Taking Advantage of volatility collapse following Earnings Results by using Advance Options strategies such as Spread and Straddles.

Since Last Earnings

Change in share price since last Earnings release.

Why is it Important?

When share has gained more than 10% since it's last Earning release, it tends to over react to minor bad news and give up some gains if not all. So, it contains more downside volatility than upside When share has dropped more than 10% since it's last Earning release, it tends to over react to minor good news and recover some drops if not all. So, it contains more upside volatility than downside.

EPS Surprise (%)

Occurs when a company's reported quarterly or annual profits are above or below analysts' expectations. Here is the formula to derive % EPS Surprice:

Actual EPS - Estimated EPS
------------------------------------- x 100
Estimated EPS

Why is it Important?

Earnings surprises can have a huge impact on a company's stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock's price, but also to a gradual increase over time. Hence, it's not surprising that some companies are known for routinely beating earning projections. A negative earnings surprise will usually result in a decline in share price.

Next Day Price Change (%)

Next Regular trading session Closing price following Earnings result.

For After Market Close Earnings, It is a next trading day closing price. For Before Market Open Earnings, It is the same trading day closing price.

Why is it Important?

Next Day price change is a reaction of Earnings result.

AGTC MENU
AGTC
CLOSE

Applied Genetic Technologies Corp (AGTC) News Today

Add to Watchlist (Why?)
AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit
AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit
October 19 2021 05:00 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the Dry AMD Therapeutic Development Summit being held virtually October 19 – 21, 2021.

AGTC Announces Two Key Leadership Team Appointments
AGTC Announces Two Key Leadership Team Appointments
October 14 2021 02:00 PM

- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - - AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations -

AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa
AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa
October 12 2021 08:08 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the 2021 Cell & Gene Meeting on the Mesa being held October 12-14, 2021.

AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
September 27 2021 05:00 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 1:20pm ET on Thursday, September 30th, 2021.

Kids Suffer Adverse Reactions In Applied Genetic
Kids Suffer Adverse Reactions In Applied Genetic's Color Blindness Gene Therapy Trial
September 24 2021 06:59 AM

After escalating the dose in its pediatric gene therapy trial, Applied Genetic Technologies Corporation (NASDAQ: AGTC) has run into safety problems.  The Company recently enrolled six pediatric achromatopsia (ACHM) with CNGB3 gene mutation and five pediatric ACHM patients with CNGA3 mutation in high dose groups 5a and 6a.

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript
September 23 2021 07:38 PM

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript

AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021
AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021
September 23 2021 01:05 PM

-Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022-

AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021
AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021
September 16 2021 05:00 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter and year ended June 30, 2021 after the market closes on Thursday, September 23, 2021. AGTC management will host a conference call beginning at 4:30 PM Eastern Time on the same date to review results and provide a corporate update.

AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07 2021 07:23 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th, 2021.

AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference
AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference
September 02 2021 06:41 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in a fireside chat at the 2021 Wells Fargo Virtual Healthcare Conference on September 10th, 2021 at 8:40am E.T.

Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community
Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community
August 24 2021 05:00 AM

WINSTON SALEM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Greater Gift of Winston Salem, a non-profit that celebrates participation in clinical trials today announced a partnership with Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company developing genetic therapies for the treatment of rare inherited retinal diseases (IRDs), and mobile vision provider 2020 On-site, a company involved in IRD clinical research and provides complimentary eye exams and facilitates the delivery of eyeglasses to students in need.

AGTC Announces Sponsorship of Achroma Corp
AGTC Announces Sponsorship of Achroma Corp's No Roadblocks Program
August 19 2021 01:05 PM

- Program helps those living with Achromatopsia receive filtered glasses and contact lenses to qualify for bioptic driving-

AGTC Appoints Ophthalmology and Retinal Disease Specialist and Industry R&D Veteran Yehia Hashad, MD to its Board of Directors
AGTC Appoints Ophthalmology and Retinal Disease Specialist and Industry R&D Veteran Yehia Hashad, MD to its Board of Directors
August 18 2021 05:00 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced the addition of Yehia Hashad, MD to its Board of Directors.

AGTC to Participate in Envision Virtual Conference East 2021 Panel Discussion
AGTC to Participate in Envision Virtual Conference East 2021 Panel Discussion
August 16 2021 05:00 AM

-AGTC patient advocacy executive director will address genetic testing and gene therapy for the treatment of rare retinal diseases-

AGTC to Participate at Upcoming Investor Conferences
AGTC to Participate at Upcoming Investor Conferences
August 02 2021 01:05 PM

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that management will be participating in the following virtual investor conferences:

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk
Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk
July 14 2021 07:47 PM

Applied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics.

AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene
AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene
June 24 2021 04:00 AM

- Activities to support the next stage of clinical development of ACHM B3 candidate are ongoing-

AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials
AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials
June 23 2021 01:03 PM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it plans to release 12-month data for adult patients and low dose pediatric patients in its Phase 1/2 clinical Achromatopsia (ACHM) trials on Thursday, June 24, 2021. AGTC management will host a conference call and webcast with accompanying slides beginning at 8:00 AM Eastern Time on the same date to review the ACHM CNGB3 and CNGA3 data and provide an update on the trials.

AGTC to Present at American Optometric Association
AGTC to Present at American Optometric Association's Optometry's Meeting
June 22 2021 04:00 AM

-AGTC patient advocacy executive director will highlight the state of gene therapy  trial recruitment for IRDs-

Is the Options Market Predicting a Spike in Applied Genetic Technologies (AGTC) Stock?
Is the Options Market Predicting a Spike in Applied Genetic Technologies (AGTC) Stock?
June 16 2021 06:46 AM

Investors need to pay close attention to Applied Genetic Technologies (AGTC) stock based on the movements in the options market lately.

7 Penny Stocks To Watch Before They Pop Due to Reddit Users
7 Penny Stocks To Watch Before They Pop Due to Reddit Users
June 11 2021 12:02 PM

Penny stocks are not usually on lists of must-buy stocks, but that does not mean these companies cannot explode in the coming weeks. The post 7 Penny Stocks To Watch Before They Pop Due to Reddit Users appeared first on InvestorPlace.

Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation's (AGTC) CEO Sue Washer on Q3 2021 Results - Earnings Call Transcript
May 17 2021 06:56 PM

Applied Genetic Technologies Corporation's (AGTC) CEO Sue Washer on Q3 2021 Results - Earnings Call Transcript

AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2021
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2021
May 17 2021 01:05 PM

- Reported 50% response rate in visual sensitivity among patients in highest dose groups in ongoing Phase 1/2 clinical trial of its XLRP gene therapy candidate for patients who met inclusion criteria for Skyline and Vista trials -

Concept Companies Breaks Ground on Expansion for AGTC in Alachua
Concept Companies Breaks Ground on Expansion for AGTC in Alachua's Foundation Park
May 14 2021 09:54 AM

GAINESVILLE, Fla., May 14, 2021 /PRNewswire/ -- Concept Companies, a Gainesville headquartered full-service real estate development and construction firm, has executed an agreement to commence development of a new laboratory facility for Applied Genetic Technologies Corporation (Nasdaq: AGTC).

5 Reddit Penny Stocks Seeing the Most Chatter Friday
5 Reddit Penny Stocks Seeing the Most Chatter Friday
May 14 2021 09:36 AM

InvestorPlace is closing out a busy week of trading with a look at the Reddit penny stocks seeing the most chatter on Friday. The post 5 Reddit Penny Stocks Seeing the Most Chatter Friday appeared first on InvestorPlace.

AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates
AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates
May 13 2021 01:03 PM

- Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility -

5 Reddit Penny Stocks Seeing the Most Chatter Thursday
5 Reddit Penny Stocks Seeing the Most Chatter Thursday
May 06 2021 10:33 AM

It's time to take another look at penny stocks that are popular on Reddit as we dive into those getting the most attention on Thursday. The post 5 Reddit Penny Stocks Seeing the Most Chatter Thursday appeared first on InvestorPlace.

Applied Genetic
Applied Genetic's XLRP Gene Therapy Shows Improved, Durable Response In Retinal Sensitivity
May 06 2021 06:04 AM

Applied Genetic Technologies Corporation (NASDAQ: AGTC) has announced additional data from the ongoing X-linked retinitis pigmentosa (XLRP) gene therapy Phase 1/2 trial, including 12-month data from Groups 5 & 6 and 24-month data from two of three Group 4 patients. Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials.

AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial
May 06 2021 04:00 AM

-Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials-

AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss XLRP Full 12-Month Data from Highest Dose Groups and 24-Month Data from a Subset of Group 4 Patients of its Ongoing Phase 1/2 Clinical Trial
AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss XLRP Full 12-Month Data from Highest Dose Groups and 24-Month Data from a Subset of Group 4 Patients of its Ongoing Phase 1/2 Clinical Trial
May 05 2021 01:05 PM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it plans to release 12-month data for Groups 5 and 6 evaluating durability of effect and continued safety at higher doses and 24-month data evaluating durability from a subset of Group 4 patients for its Phase 1/2 clinical trial in patients with X-linked Retinitis Pigmentosa (XLRP) on Thursday, May 6, 2021. AGTC management will host a conference call and webcast with accompanying slides to review the data and provide a general update on the XLRP trial beginning at 8:00 AM Eastern Time on the same date.

AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
May 04 2021 05:00 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the presentation of two abstracts at the upcoming American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting. The abstracts report new data from research-stage retinal studies of novel AAV vectors to support clinical phase product release for the X-linked retinitis pigmentosa (XLRP) clinical Phase 2/3 Vista study and manufacturing process improvements for future clinical trials. The ASGCT Annual Meeting is being held virtually May 11-14, 2021.

AGTC Clinical Investigators Provide Encore Presentation of Data from the Company
AGTC Clinical Investigators Provide Encore Presentation of Data from the Company's Ongoing XLRP and Achromatopsia Phase 1/2 Trials
May 03 2021 05:39 AM

-Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021-

AGTC Announces Data to be Presented from the Ongoing XLRP and Achromatopsia Clinical Trials at the ARVO 2021 Virtual Annual Meeting
AGTC Announces Data to be Presented from the Ongoing XLRP and Achromatopsia Clinical Trials at the ARVO 2021 Virtual Annual Meeting
April 29 2021 04:30 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that data from the ongoing X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) clinical trials will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting. Paul Yang, MD, PhD, will present interim data from the XLRP Phase 1/2 trial and Mark Pennesi, MD, PhD, will present interim data from the ACHM Phase 1/2 clinical trials.

AGTC Announces Departure of Chief Scientific Officer
AGTC Announces Departure of Chief Scientific Officer
April 26 2021 01:02 PM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Mark Shearman, Ph.D., Chief Scientific Officer, has resigned from the company to pursue another opportunity but will remain to facilitate a smooth transition through June 4, 2021.

TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program
TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program
April 13 2021 04:00 AM

- AGTC Transfers Clinical Trial Materials and Phase 1/2 Data To TeamedON -

AGTC to Participate in Upcoming Virtual Biotech Corporate Access Day and Cell and Gene Conference
AGTC to Participate in Upcoming Virtual Biotech Corporate Access Day and Cell and Gene Conference
March 31 2021 05:00 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Company management will participate in the following virtual conferences:

AGTC Announces New Initiatives To Enhance The Patient Journey In Its XLRP Trials
AGTC Announces New Initiatives To Enhance The Patient Journey In Its XLRP Trials
March 25 2021 04:00 AM

-AGTC's deep commitment to the patient voice drives solutions to support patient access to information and to improve the experience of patients participating in clinical trials-

AGTC to Present at the Gene Therapy Patient Engagement Summit, Held Virtually, March 24, 2021
AGTC to Present at the Gene Therapy Patient Engagement Summit, Held Virtually, March 24, 2021
March 18 2021 09:00 AM

-AGTC will highlight the value of the patient voice in gene therapy development-

7 Small Stocks Up Big Can Still Double From Here, Analysts Say
7 Small Stocks Up Big Can Still Double From Here, Analysts Say
March 04 2021 06:00 AM

Getting a big headache watching large-cap S&P 500 stocks lose steam? Small-cap stocks are giving investors a new way to make big money.

AGTC to Present at Upcoming Investor Conferences
AGTC to Present at Upcoming Investor Conferences
March 02 2021 05:00 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in the following virtual investor conferences:

AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021
AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021
February 16 2021 10:00 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President & Chief Executive Officer, will participate at the OIS Gene Therapy Innovation Showcase, taking place virtually on Thursday, February 18, 2021 from 12:00 PM to 3:00 PM CST.

AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021
AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021
February 16 2021 06:00 AM

-AGTC executives will address critical success factors in gene therapy manufacturing and the value of the patient perspective in gene therapy development ---- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Dave Knop, Vice President of Process Development, and Jill Dolgin, PharmD, Executive Director of Patient Advocacy, will present at the 4th Annual Gene Therapy for Rare Disorders digital event taking place February 22-25, 2021.

Applied Genetic Technologies: Leader Among Larger Peers In Gene Therapies For Certain Eye Diseases
Applied Genetic Technologies: Leader Among Larger Peers In Gene Therapies For Certain Eye Diseases
February 16 2021 06:00 AM

AGTC leads the pack among Biogen, JNJ and MeiraGTx in developing gene therapies for certain eye diseases. Cash balance is decent.

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q2 2021 Results - Earnings Call Transcript
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q2 2021 Results - Earnings Call Transcript
February 11 2021 01:05 PM

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q2 2021 Results - Earnings Call Transcript

AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2020
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2020
February 11 2021 05:00 AM

- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022 -

AGTC Executives Awarded First Place in the BioProcess International Reader
AGTC Executives Awarded First Place in the BioProcess International Reader's Choice Awards, Cell & Gene Therapies Category
February 04 2021 10:03 AM

Article reflects Company's leadership and innovation in scalable, reproducible manufacture of adeno-associated virus (AAV)-based gene therapies

AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 11, 2021
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 11, 2021
February 04 2021 05:00 AM

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the fiscal quarter ended December 31, 2020 before the market opens on Thursday, February 11, 2021. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same date to review results and provide a corporate update.

AGTC Announces Pricing of Public Offering of Common Stock and Warrants
AGTC Announces Pricing of Public Offering of Common Stock and Warrants
January 28 2021 06:07 AM

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the pricing of its previously announced underwritten public offering of 16,741,573 shares of its common stock, together with accompanying warrants to purchase 8,370,786 shares of common stock. The common stock will be sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock sold. The combined offering price to the public of each share of common stock and accompanying warrant is $4.45. The warrants must be exercised in integral multiples of two and will have an exercise price of $6.00 per share, will be immediately exercisable and will have a term of five years from the date of issuance. The gross proceeds to AGTC from this offering are expected to be approximately $74.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by AGTC. All of the securities are being sold by AGTC. The offering is expected to close on or about February 1, 2021, subject to customary closing conditions.

AGTC Announces Proposed Public Offering of Common Stock and Warrants
AGTC Announces Proposed Public Offering of Common Stock and Warrants
January 27 2021 02:35 PM

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it is offering to sell shares of its common stock and pre-funded warrants, together with accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are being sold by AGTC. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials
AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials
January 27 2021 02:19 PM

-Preliminary results suggest sustained improvements to 12-months in visual sensitivity, as measured by full field static perimetry, supported in some patients by other endpoints- -Company plans longer term follow-up, dosing of younger pediatric patients, and addition of new brain imaging and color brightness tests-

Join over 100,000 investors who get daily notable Earnings alerts with predicted move.